Cyclosporine药物市场报告：2031 年趋势、预测与竞争分析

全球Cyclosporine药物市场前景光明，在移植排斥预防、类风湿性关节炎、干癣、干眼症和自体免疫重症肌无力市场都存在机会。预计2025年至2031年期间，全球Cyclosporine药物市场的复合年增长率将达到17.3%。这个市场的主要驱动因素包括类风湿性关节炎和干癣等自体免疫疾病的盛行率不断上升、全球器官移植数量的不断增加以及药物输送系统的不断进步。

• Lucintel 预测口服药物在预测期内将出现高速成长。
• 根据应用情况，预防移植排斥预计将实现最高成长。
• 根据地区来看，预计亚太地区将在预测期内实现最高成长。

Cyclosporine药物市场的新趋势

由于专利到期、非专利竞争以及药物输送技术的进步，免疫抑制必需Cyclosporine药物市场正在快速发展。改善患者疗效、控制副作用、确保成本效益是塑造市场的关键驱动因素。这些因素催生了若干关键趋势，这些趋势将影响Cyclosporine的配製、给药方式以及患者取得方式。这些趋势不仅影响市场动态，也有助于改善患者的治疗和疗效。

• 非专利的兴起：原研究Cyclosporine药物专利到期为学名药的进入铺平了道路。竞争加剧压低了药品价格，使更多患者负担得起Cyclosporine治疗。学名药的兴起对市场占有率和定价产生了重大影响。
• 专注于改进药物传输系统：目前正在开发新的药物传输系统，以提高Cyclosporine的生物有效性并减少其副作用。这些进展旨在提高患者的依从性、疗效和整体治疗效果。输送系统的改进对于优化Cyclosporine治疗至关重要。
• 个人化医疗和治疗药物监测 (TDM)：Cyclosporine的治疗窗较窄，需要仔细的剂量监测。 TDM 的日益普及使得个别化给药成为可能，从而优化疗效并最大程度降低毒性。这一趋势正在改善患者的安全性和疗效。
• 注重成本效益：医疗保健系统越来越注重成本控制，这推动了对高性价比Cyclosporine剂型和治疗策略的需求。成本效益是影响市场进入和报销决策的主要因素。
• 新型类似物和生物类似物的开发：研发重点是开发具有更优药物动力学特性和更低副作用的新型Cyclosporine类似物和生物类似物。这些进展可望进一步改善患者预后并拓展治疗选择。

总的来说，这些趋势正在重塑Cyclosporine药物市场，提高药物可负担性、改善药物传递、个人化治疗、注重成本效益，进而改善患者的用药管道、改善治疗效果、增加市场竞争。

Cyclosporine药物市场的最新趋势

免疫抑制必需Cyclosporine药物市场充满活力，受专利到期、学名药竞争以及药物输送技术进步的驱动。优化疗效、控制副作用和确保成本效益是关键驱动因素。近期趋势反映了这些影响，重点是配方改进、生物相似药和以患者为中心的治疗方案。这些进步正在再形成市场，影响药物的可及性、治疗效果和竞争格局。

• Cyclosporine非专利药供应增加：专利到期导致Cyclosporine学名药製剂激增。这显着增强了市场竞争，降低了价格，并改善了患者获得这种必需药物的管道。学名药的供应提供了更多的治疗选择，尤其是在成本敏感的市场。
• 新型製剂的开发：製药公司正在投资开发具有改进药物动力学特征的新型Cyclosporine剂型。这些製剂旨在提高生物有效性、减少副作用并改善患者依从性。这些进展提高了Cyclosporine的治疗指数，从而改善了患者的生活品质。
• Cyclosporine生物相似药的出现：Cyclosporine生物相似药已进入市场，为原厂生物製药提供了经济高效的替代品。生物相似药经过严格测试，证明与原厂产品一样安全有效，在扩大治疗选择的同时，降低了医疗成本。
• 着重个人化医疗：治疗药物监测 (TDM) 在Cyclosporine治疗中发挥日益重要的作用。基于 TDM 的个人化给药可以优化药物浓度，最大限度地提高疗效，并最大限度地降低毒性。这种以患者为中心的方法改善了治疗效果，并减少了不利事件。
• 重视病患援助项目：製药公司和医疗保健机构正在实施病患援助项目，以提高病患对Cyclosporine治疗的依从性。这些计画提供教育、咨询和经济援助，以解决治疗障碍并改善长期疗效。此类项目能够加强与患者的关係，并提高治疗成功率。

这些新兴市场的发展对Cyclosporine药物市场产生了集体影响，包括提高可负担性、改善药物输送和疗效、增加个人化医疗和加强患者倡导，这将改善患者的可及性、改善治疗结果和增加市场竞争，最终使需要长期免疫抑制的患者受益。

目录

第一章执行摘要

第二章全球Cyclosporine药物市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球Cyclosporine药物市场趋势（2019-2024）及预测（2025-2031）
• 全球Cyclosporine药物市场类型
  • 口服
  • 肠外
• 全球Cyclosporine药物市场（按应用）
  • 预防移植排斥
  • 类风湿性关节炎
  • 干癣
  • 眼睛干涩
  • 自体免疫重症肌无力
  • 其他的

第四章区域市场趋势与预测分析（2019-2031）

• 全球Cyclosporine药物市场（按地区）
• 北美Cyclosporine药物市场
• 欧洲Cyclosporine药物市场
• 亚太地区Cyclosporine药物市场
• 世界其他地区的Cyclosporine药物市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球Cyclosporine药物市场成长机会（按类型）
  • 全球Cyclosporine药物市场的成长机会（按应用）
  • 全球Cyclosporine药物市场各区域成长机会
• 全球Cyclosporine药物市场的新趋势
• 战略分析
  • 新产品开发
  • 全球Cyclosporine药物市场的产能扩张
  • 全球Cyclosporine药物市场的企业合併
  • 认证和许可

第七章主要企业简介

• AbbVie
• Allergan
• Apotex
• Mayne Pharma Group
• Mckesson Medical Surgical
• Novartis
• Otsuka Pharmaceutical
• Regenerx Biopharmaceuticals
• Santen Pharmaceuticals
• Sun Pharmaceuticals Industries

The future of the global cyclosporine drug market looks promising with opportunities in the transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, dry eye, and autoimmune myasthenia gravis markets. The global cyclosporine drug market is expected to grow with a CAGR of 17.3% from 2025 to 2031. The major drivers for this market are the increasing prevalence of autoimmune diseases such as rheumatoid arthritis & psoriasis, the rising number of organ transplant procedures globally, and the growing advancements in drug delivery systems.

• Lucintel forecasts that, within the type category, oral is expected to witness higher growth over the forecast period.
• Within the application category, transplant rejection prophylaxis is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Cyclosporine Drug Market

The cyclosporine drug market, essential for immunosuppression, is evolving rapidly due to patent expirations, generic competition, and advancements in drug delivery. Improving patient outcomes, managing side effects, and ensuring cost-effectiveness are key drivers shaping the market. These factors are leading to the emergence of several significant trends, impacting how cyclosporine is formulated, administered, and accessed by patients. These trends are not only influencing market dynamics but also improving patient care and treatment outcomes.

• Rise of Generic Formulations: Patent expirations of branded cyclosporine drugs have paved the way for the entry of generic versions. This increased competition is driving down drug prices, making cyclosporine therapy more affordable and accessible to a wider patient population. The rise of generics is significantly impacting market share and affordability.
• Focus on Improved Drug Delivery Systems: Novel drug delivery systems are being developed to enhance bioavailability and reduce the side effects associated with cyclosporine. These advancements aim to improve patient compliance, therapeutic efficacy, and overall treatment outcomes. Improved delivery systems are crucial for optimizing cyclosporine therapy.
• Personalized Medicine and Therapeutic Drug Monitoring (TDM): Cyclosporine's narrow therapeutic window necessitates careful dose monitoring. The increasing use of TDM allows for personalized dosing, optimizing efficacy, and minimizing toxicity. This trend is improving patient safety and treatment outcomes.
• Emphasis on Cost-Effectiveness: Healthcare systems are increasingly focused on cost containment. This is driving the demand for cost-effective cyclosporine formulations and treatment strategies. Cost-effectiveness is a major factor influencing market access and reimbursement decisions.
• Development of Novel Analogs and Biosimilars: Research and development efforts are focused on creating novel cyclosporine analogs and biosimilars with improved pharmacokinetic profiles and reduced side effects. These advancements have the potential to further improve patient outcomes and expand treatment options.

These trends are collectively reshaping the cyclosporine drug market by increasing affordability, improving drug delivery, personalizing treatment, and focusing on cost-effectiveness. They are leading to better patient access, improved treatment outcomes, and a more competitive market landscape.

Recent Developments in the Cyclosporine Drug Market

The cyclosporine drug market, vital for immunosuppression, is dynamic, influenced by patent expirations, generic competition, and advancements in drug delivery. Optimizing efficacy, managing side effects, and ensuring cost-effectiveness are key drivers. Recent developments reflect these influences, with a focus on improved formulations, biosimilars, and patient-centric approaches. These advancements are reshaping the market, impacting accessibility, treatment outcomes, and the competitive landscape.

• Increased Availability of Generic Cyclosporine: Patent expirations have led to a surge in generic cyclosporine formulations. This has significantly increased market competition, driving down prices and improving patient access to this essential medication. The availability of generics has broadened treatment options, particularly in cost-sensitive markets.
• Development of Novel Formulations: Pharmaceutical companies are investing in developing novel cyclosporine formulations with improved pharmacokinetic profiles. These formulations aim to enhance bioavailability, reduce side effects, and improve patient compliance. These advancements are improving the therapeutic index of cyclosporine and enhancing patient quality of life.
• Emergence of Cyclosporine Biosimilars: Biosimilar versions of cyclosporine are entering the market, offering cost-effective alternatives to branded biologics. Biosimilars are rigorously tested to demonstrate comparable safety and efficacy to the reference product, expanding treatment options while managing healthcare costs.
• Focus on Personalized Medicine: Therapeutic drug monitoring (TDM) is playing an increasingly important role in cyclosporine therapy. Personalized dosing based on TDM allows for optimizing drug levels, maximizing efficacy, and minimizing toxicity. This patient-centric approach is improving treatment outcomes and reducing adverse events.
• Emphasis on Patient Support Programs: Pharmaceutical companies and healthcare providers are implementing patient support programs to improve adherence to cyclosporine therapy. These programs offer education, counseling, and financial assistance, addressing barriers to treatment and improving long-term outcomes. Such programs enhance patient engagement and optimize treatment success.

These developments are collectively impacting the cyclosporine drug market by increasing affordability, improving drug delivery and efficacy, promoting personalized medicine, and enhancing patient support. They are leading to better patient access, improved treatment outcomes, and a more competitive market landscape, ultimately benefiting patients requiring long-term immunosuppression.

Strategic Growth Opportunities in the Cyclosporine Drug Market

The cyclosporine drug market, crucial for immunosuppression, is evolving with growth opportunities driven by increasing transplant procedures, autoimmune disease prevalence, and advancements in drug delivery. While generic competition impacts pricing, the need for effective and personalized immunosuppression creates avenues for innovation and market expansion. These opportunities focus on optimizing cyclosporine therapy for specific patient populations and improving long-term outcomes. Capitalizing on these opportunities requires a strategic focus on research, development, and patient-centric approaches.

• Expanding Organ Transplantation: The increasing success rates of organ transplantation are driving the demand for cyclosporine as a cornerstone of immunosuppressive regimens. Growth opportunities exist in developing tailored cyclosporine therapies for specific organ transplants, improving graft survival rates, and minimizing long-term complications. This focus enhances transplant outcomes and expands the pool of eligible recipients.
• Autoimmune Disease Management: Cyclosporine's efficacy in managing various autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, presents significant growth opportunities. Developing targeted cyclosporine formulations for specific autoimmune conditions can improve treatment outcomes and reduce the burden of these chronic illnesses.
• Pediatric and Geriatric Populations: Specialized cyclosporine formulations and dosing strategies for pediatric and geriatric patients represent a key growth area. These populations often require adjusted dosing and careful monitoring due to differences in metabolism and potential comorbidities. Tailored therapies can optimize safety and efficacy in these vulnerable groups.
• Novel Drug Delivery Systems: Advancements in drug delivery, such as nanoparticles and sustained-release formulations, offer opportunities to improve cyclosporine bioavailability, reduce side effects, and enhance patient compliance. These innovations can improve therapeutic outcomes and quality of life for patients requiring long-term immunosuppression.
• Combination Therapies: Exploring combination therapies involving cyclosporine and other immunosuppressants or immunomodulators presents growth opportunities for optimizing treatment protocols. Such approaches can potentially reduce cyclosporine dosage, minimize toxicity, and improve long-term outcomes in transplant recipients and patients with autoimmune diseases.

These growth opportunities are collectively impacting the cyclosporine drug market by driving innovation in drug delivery, expanding treatment options for various patient populations, and promoting personalized medicine approaches. They are contributing to improved patient outcomes, enhanced quality of life, and a more competitive market landscape, ultimately benefiting patients requiring effective and well-tolerated immunosuppression.

Cyclosporine Drug Market Driver and Challenges

The cyclosporine drug market, vital for immunosuppression, is shaped by a complex interplay of drivers and challenges. These factors encompass technological advancements in drug delivery, economic pressures from generic competition, evolving regulatory landscapes, and the increasing demand for personalized medicine. Understanding these influences is crucial for navigating this dynamic market and ensuring access to effective and affordable cyclosporine therapy. These drivers and challenges are influencing research and development, pricing strategies, and patient access to this essential medication.

The factors responsible for driving the cyclosporine drug market include:

1. Rising Prevalence of Organ Transplants: The increasing success and frequency of organ transplantation procedures drive the demand for effective immunosuppressant drugs like cyclosporine. As transplant rates rise, the need for long-term immunosuppression, including cyclosporine-based regimens, also increases, fueling market growth.

2. Growing Burden of Autoimmune Diseases: The rising prevalence of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, contributes to the demand for cyclosporine. Cyclosporine's efficacy in managing these conditions makes it a valuable therapeutic option, driving market expansion.

3. Advancements in Drug Delivery: Innovations in drug delivery systems, such as nanoparticles and modified-release formulations, are improving cyclosporine's bioavailability and reducing side effects. These advancements enhance patient compliance and therapeutic outcomes, driving market growth for advanced formulations.

4. Focus on Personalized Medicine: The increasing emphasis on personalized medicine and therapeutic drug monitoring (TDM) is influencing the cyclosporine market. TDM allows for individualized dosing, optimizing efficacy and minimizing toxicity, leading to better patient management and potentially increased drug utilization.

5. Expanding Healthcare Access: Improved healthcare access in many regions is increasing the availability of organ transplantation and treatment for autoimmune diseases. This expansion in access contributes to the demand for cyclosporine, particularly in emerging markets.

Challenges in the cyclosporine drug market are:

1. Generic Competition and Price Erosion: Patent expirations have led to the entry of numerous generic cyclosporine formulations, significantly increasing market competition and driving down prices. This price erosion, while beneficial for patients, can impact profitability for pharmaceutical companies.

2. Safety and Toxicity Concerns: Cyclosporine's narrow therapeutic window and potential for serious side effects, such as nephrotoxicity and hypertension, pose a significant challenge. Managing these risks requires careful monitoring and dose adjustments, adding complexity to treatment.

3. Regulatory Scrutiny: Stringent regulatory requirements for new cyclosporine formulations and biosimilars can be a challenge. Meeting these requirements, including demonstrating bioequivalence and safety, can be costly and time-consuming, impacting market entry for new products.

These drivers and challenges collectively shape the cyclosporine drug market. While the drivers create opportunities for growth and innovation, the challenges related to generic competition, safety concerns, and regulatory hurdles must be addressed strategically. The market's future will depend on balancing affordability, efficacy, and safety to ensure optimal patient care and access to this critical medication.

List of Cyclosporine Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cyclosporine drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cyclosporine drug companies profiled in this report include-

• AbbVie
• Allergan
• Apotex
• Mayne Pharma Group
• McKesson Medical Surgical
• Novartis
• Otsuka Pharmaceutical
• Regenerx Biopharmaceuticals
• Santen Pharmaceuticals
• Sun Pharmaceuticals Industries

Cyclosporine Drug Market by Segment

The study includes a forecast for the global cyclosporine drug market by type, application, and region.

Cyclosporine Drug Market by Type [Value from 2019 to 2031]:

• Oral
• Parenteral

Cyclosporine Drug Market by Application [Value from 2019 to 2031]:

• Transplant Rejection Prophylaxis
• Rheumatoid Arthritis
• Psoriasis
• Dry Eye
• Autoimmune Myasthenia Gravis
• Others

Cyclosporine Drug Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Cyclosporine Drug Market

The cyclosporine drug market, crucial for immunosuppression in organ transplantation and autoimmune diseases, is experiencing a dynamic period marked by patent expirations, the rise of generics, and evolving formulations. Cyclosporine's narrow therapeutic window necessitates careful monitoring and personalized dosing, making advancements in drug delivery and therapeutic drug monitoring (TDM) significant. Furthermore, cost-effectiveness and accessibility are key factors influencing market dynamics, particularly in emerging economies. These factors are driving innovation and competition within the cyclosporine market globally.

• United States: The US market is mature, with a strong presence of both branded and generic cyclosporine formulations. Focus is on bioequivalence studies for generics and the development of novel drug delivery systems to improve patient compliance and reduce side effects. The high cost of healthcare in the US continues to be a major factor influencing market access and reimbursement policies.
• China: The Chinese cyclosporine market is growing rapidly, driven by increasing organ transplantation procedures and rising healthcare expenditure. Domestic pharmaceutical companies are focusing on developing generic versions of cyclosporine, which is increasing market competition. Accessibility and affordability are key concerns in this market.
• Germany: Germany has a well-established cyclosporine market, with a strong emphasis on quality and efficacy. The market is characterized by a high adoption of advanced formulations and a focus on personalized medicine. Germany's robust healthcare system ensures patient access to cyclosporine therapy.
• India: The Indian cyclosporine market is expanding, driven by a large population and growing awareness of autoimmune diseases. Generic manufacturers play a significant role, making cyclosporine more affordable and accessible. The focus is on developing cost-effective formulations and improving drug delivery systems.
• Japan: Japan has a mature cyclosporine market, with a focus on high-quality generics and innovative formulations. The market is characterized by a strong regulatory framework and a focus on patient safety. Japan's aging population contributes to the demand for cyclosporine for age-related autoimmune conditions.

Features of the Global Cyclosporine Drug Market

Market Size Estimates: Cyclosporine drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Cyclosporine drug market size by type, application, and region in terms of value ($B).

Regional Analysis: Cyclosporine drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the cyclosporine drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cyclosporine drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cyclosporine drug market by type (oral and parenteral), application (transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, dry eye, autoimmune myasthenia gravis, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cyclosporine Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Cyclosporine Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Cyclosporine Drug Market by Type
  • 3.3.1: Oral
  • 3.3.2: Parenteral
• 3.4: Global Cyclosporine Drug Market by Application
  • 3.4.1: Transplant Rejection Prophylaxis
  • 3.4.2: Rheumatoid Arthritis
  • 3.4.3: Psoriasis
  • 3.4.4: Dry Eye
  • 3.4.5: Autoimmune Myasthenia Gravis
  • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Cyclosporine Drug Market by Region
• 4.2: North American Cyclosporine Drug Market
  • 4.2.1: North American Market by Type: Oral and Parenteral
  • 4.2.2: North American Market by Application: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Dry Eye, Autoimmune Myasthenia Gravis, and Others
• 4.3: European Cyclosporine Drug Market
  • 4.3.1: European Market by Type: Oral and Parenteral
  • 4.3.2: European Market by Application: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Dry Eye, Autoimmune Myasthenia Gravis, and Others
• 4.4: APAC Cyclosporine Drug Market
  • 4.4.1: APAC Market by Type: Oral and Parenteral
  • 4.4.2: APAC Market by Application: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Dry Eye, Autoimmune Myasthenia Gravis, and Others
• 4.5: ROW Cyclosporine Drug Market
  • 4.5.1: ROW Market by Type: Oral and Parenteral
  • 4.5.2: ROW Market by Application: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Dry Eye, Autoimmune Myasthenia Gravis, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Cyclosporine Drug Market by Type
  • 6.1.2: Growth Opportunities for the Global Cyclosporine Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Cyclosporine Drug Market by Region
• 6.2: Emerging Trends in the Global Cyclosporine Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Cyclosporine Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cyclosporine Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: AbbVie
• 7.2: Allergan
• 7.3: Apotex
• 7.4: Mayne Pharma Group
• 7.5: Mckesson Medical Surgical
• 7.6: Novartis
• 7.7: Otsuka Pharmaceutical
• 7.8: Regenerx Biopharmaceuticals
• 7.9: Santen Pharmaceuticals
• 7.10: Sun Pharmaceuticals Industries